TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06459765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mi2000 TICI
Description: Cochlear Implantation
Study: NCT05423054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Description: * Patients will be positioned on their back while their knees will be flexed.~* Each patient will receive a 15-minute abdominal massage intervention half an hour before enteral feeding twice per day and the interval between two massages is 2 hours for consecutive 3 days.~* The PR will be standed on the right side of the patient during the massage practice.~* The abdominal massage technique will be delivered to each patient in four consecutive strokes including stroking, effleurage, kneading and vibration.
Study: NCT05077527

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study: NCT05504395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSTI-500
Description: Single 10 mg capsule
Study: NCT05982548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR intervention
Description: VR intervention of no more than 7 minutes~Participants viewed the home as a first person character and experience psychotic phenomena including auditory hallucinations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VR control intervention
Description: VR intervention of no more than 7 minutes~Participants viewed the same home as a first person character without psychotic phenomena
Study: NCT06417125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: Patients were premedicated with intranasal dexmedetomidine 2 μg/kg in the holding area.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Patients were premedicated with oral midazolam 0.5 mg/kg in the holding area.
Study: NCT06073847

Intervention type: DRUG
Intervention: Fedratinib
Description: According to the approved label
Study: NCT06417125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal Saline
Description: Patients were premedicated with normal saline 0.02 mL/kg in the holding area.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: Patients were premedicated with normal saline 0.02 mL/kg in the holding area.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose solution
Description: Patients were premedicated with oral sweet solution 0.25 mL/kg in the holding area.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose solution
Description: Patients were premedicated with oral sweet solution 0.25 mL/kg in the holding area.
Study: NCT06300840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BalanceBelt
Description: The vibrotactile belt (i.e., Elitac BalanceBelt®) supports patients with severe balance disorders by substituting the missing balance information with vibrations (haptic feedback).
Study: NCT06383767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESG401
Description: IV infusion on day 1,8, and 15 of each 28 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)
Description: Eribulin, capecitabine, gemcitabine or vinorelbine
Study: NCT06300840

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BalanceBelt
Description: The vibrotactile belt (i.e., Elitac BalanceBelt®) supports patients with severe balance disorders by substituting the missing balance information with vibrations (haptic feedback).
Study: NCT06196528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WristArt implant
Description: implantation of the WristArt implant
Study: NCT06265051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Tirofiban 5μg/kg was administered intravenously through the catheter artery at a rate of 1ml/min, followed by an intravenous infusion of 0.1μg/(kg·min) for 24 hours. Standard medical treatment was administered after the surgery.
Study: NCT05951595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine-Amodiaquine (ALAQ)
Description: A new fixed-dose combination containing artemether, lumefantrine and amodiaquine (ALAQ) will be used in the trial. Each paediatric (dispersible) tablet will contain 20 mg artemether, 120 mg lumefantrine, 40 mg amodiaquine. Adult (hard) tablets will contain either 50 mg or 60 mg of artemether, 300 or 360 mg of lumefantrine and 100 or 120 mg of amodiaquine. The treatments will be administered in 6 doses over 3 days at H0, H8, H24, H36, H48 and H60. The target dosing will be in line with the ranges recommended by the WHO (total dose of 5-24 mg/kg of artemether, 29-144 mg/ kg of lumefantrine, 22.5-45 mg/kg of amodiaquine).
Study: NCT06265051

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Saline placebo was administered in the same manner as tirofiban group. Standard medical treatment was administered after the surgery.
Study: NCT06341764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab 1120 mg
Description: Durvalumab 1120 mg day 1 i.v

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg
Description: Durvalumab i.v. at 1500 mg once every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab i.v. at 300 mg
Description: Single dose

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 25 mg/mq i.v
Description: Four cycles
Study: NCT05797870

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Selective Internal Radiation Therapy with 188Re-SSS lipiodol
Description: The treatment with 188Re-SSS lipiodol SIRT requires two steps during the patient's hospitalization: the pre-treatment simulation step and the treatment step itself.~Pre-therapeutic simulation is performed during the screening phase, before definite patient inclusion, and is composed of two procedures: a diagnostic liver angiography and a liver perfusion scintigraphy (MAA scan and SPECT/CT).~The therapeutic stage is also composed of two procedures a therapeutic liver angiography with 188Re-SSS lipiodol and a 188Re-SSS lipiodol SPECT/CT.
Study: NCT06341764

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM) 1000 mg/mq i.v.
Description: Days 1 and 8 every 21 days
Study: NCT05554575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BT-007 CD7 CAR-T cells
Description: T cells purified from the peripheral blood mononuclear cell (PBMC) of subjects or subjects' relatives which depend on their conditions, transduced with 4-1BB/CD3ζ lentiviral vector, expanded in vitro for future administration.
Study: NCT05213000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 90 minute exercise session
Study: NCT06102915

Intervention type: DRUG
Intervention: Rocuronium Bromide 10 MG/ML
Description: Comparative

Intervention type: DRUG
Intervention: Nimbex 10 MG in 5 ML Injection
Description: Comparative
Study: NCT05951595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-Lumefantrine (AL)
Description: A fixed-dose combination of AL will be used in the trial. Each paediatric (dispersible) or adult (non-dispersible) tablet will contain 20 mg artemether, 120 mg lumefantrine and will be administered in 6 doses over 3 days at H0, H8, H24, H36, H48 and H60. The target dosing will be in line with the ranges recommended by the WHO (total dose of 5-24 mg/kg of artemether, 29-144 mg/ kg of lumefantrine).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate-Amodiaquine (ASAQ)
Description: ASAQ will also be administered as a fixed dose combination. The tablets will contain 25 mg of artesunate and 67.5 mg of amodiaquine in the paediatric formulation and 100 mg artesunate, 270 mg amodiaquine in the adult formulation. The dosing will be administered once a day for 3 days at H0, H24 and H48 according to the schedule currently recommended by the WHO.
Study: NCT05844397

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WaveLight EX500 Excimer Laser System
Description: LASIK Refractive Surgery Using Contura with Phorcides

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VisuMax Surgical Laser
Description: SMILE Refractive Surgery
Study: NCT06188585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UI-EWD
Description: Hemostatic powder administered at index endoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Conventional endoscopic therapy (bipolar electrocoagulation or clips, with or without epinephrine injection) administered at index endoscopy
Study: NCT05794087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clean Air
Description: Subjects will be exposed to clean air for 3 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clean Air
Description: Subjects will be exposed to clean air for 3 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Subjects will be exposed to 0.2 ppm ozone for 3 hours.
Study: NCT05731661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day hospitalization in support care with meeting with support care professionals and coordination of actions by the advanced practice nurse
Description: During this day hospitalization, patients will meet with different specialized professionals depending on the support care needs identified.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delivery of useful information according to support care needs, concerning support care professionals in the city
Description: Delivery of useful information according to support care needs, concerning support care professionals in the city

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delivery of a personalized post-cancer plan
Description: Delivery of a personalized post-cancer plan

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delivery of a personalized post-cancer plan
Description: Delivery of a personalized post-cancer plan

Intervention type: OTHER
Group type: OTHER
Intervention: Delivery of a personalized post-cancer plan
Description: Delivery of a personalized post-cancer plan
Study: NCT05262972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservatory treatment
Description: Personalized plantar orthosis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Innovate treatment
Description: Personalized plantar orthosis + percutaneous electrolysis
Study: NCT05189587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial electrical stimulation (TES)
Description: Transcranial electrical stimulation (tES) is a noninvasive brain stimulation technique that passes an electrical current through the cortex of the brain to alter brain function. The electrical current is applied to an individual's scalp usually via two or more electrodes, and whilst a large amount of the current is conducted between electrodes through soft tissue and skull (Vöröslakos et al. 2018), a portion of the current penetrates the scalp and is conducted through the brain, where it can alter neuronal excitability. By altering the activity of brain regions involved with a behaviour of interest, investigators can observe the resulting behavioral changes and so establish a causal link between the two (Reed et al. 2018).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial electrical stimulation (TES)
Description: Transcranial electrical stimulation (tES) is a noninvasive brain stimulation technique that passes an electrical current through the cortex of the brain to alter brain function. The electrical current is applied to an individual's scalp usually via two or more electrodes, and whilst a large amount of the current is conducted between electrodes through soft tissue and skull (Vöröslakos et al. 2018), a portion of the current penetrates the scalp and is conducted through the brain, where it can alter neuronal excitability. By altering the activity of brain regions involved with a behaviour of interest, investigators can observe the resulting behavioral changes and so establish a causal link between the two (Reed et al. 2018).
Study: NCT05980468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Description: Music intervention sessions will be applied to each participant for 5 weeks, 3 days a week, 20 minutes per session.
Study: NCT06380270

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral probiotic Streptococcus salivarius eK12 sachet
Description: Bactoblis® EVOL (containing 10 billion CFU of S. salivarius eK12)
Study: NCT05988229

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toolkit to improve discharge equity
Description: Linguistically appropriate discharge teaching aids: a medication calendar, pictographics added to the after visit summary (AVS), and an audio recording of the discharge teaching.
Study: NCT05794087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Subjects will be exposed to 0.2 ppm ozone for 3 hours.
Study: NCT04993560

Intervention type: BIOLOGICAL
Intervention: BBIBP-CorV
Description: Inactivated virus COVID-19 vaccine

Intervention type: BIOLOGICAL
Intervention: BNT162b2
Description: mRNA-based COVID-19 vaccine
Study: NCT05780996

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QMODE +
Description: Atrial fibrillation radiofrequency ablation of the anterior and posterior wall with 90W (vHPSD)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QMODE
Description: Atrial fibrillation radiofrequency ablation of the anterior wall with 50W (HPSD). Ablation of the posterior wall with 90 W (vHPSD)
Study: NCT05108506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Strict need to void following surgery
Description: Certain patient will be randomized without a strict need to void prior to discharge following surgery.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Strict need to void following surgery
Description: Certain patient will be randomized with a strict need to void prior to discharge following surgery.
Study: NCT05703802

Intervention type: DIAGNOSTIC_TEST
Intervention: Procalcitonin-variants ELISA-Assay
Description: Observational study measuring procalcitonin-variants in different patient collectives by obtaining 3 blood collection tubes per patient.

Intervention type: DIAGNOSTIC_TEST
Intervention: Procalcitonin-variants ELISA-Assay
Description: Observational study measuring procalcitonin-variants in different patient collectives by obtaining 3 blood collection tubes per patient.

Intervention type: DIAGNOSTIC_TEST
Intervention: Procalcitonin-variants ELISA-Assay
Description: Observational study measuring procalcitonin-variants in different patient collectives by obtaining 3 blood collection tubes per patient.

Intervention type: DIAGNOSTIC_TEST
Intervention: Procalcitonin-variants ELISA-Assay
Description: Observational study measuring procalcitonin-variants in different patient collectives by obtaining 3 blood collection tubes per patient.

Intervention type: DIAGNOSTIC_TEST
Intervention: Procalcitonin-variants ELISA-Assay
Description: Observational study measuring procalcitonin-variants in different patient collectives by obtaining 3 blood collection tubes per patient.

Intervention type: DIAGNOSTIC_TEST
Intervention: Procalcitonin-variants ELISA-Assay
Description: Observational study measuring procalcitonin-variants in different patient collectives by obtaining 3 blood collection tubes per patient.
Study: NCT05813210

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Exercise in combination with biomarkers and pharmacological stress CMR test
Description: A bicycle ergometry combined with pharmacoligical stress test is performed. High sensitive Troponin is taken before and after the stress test.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Exercise in combination with biomarkers and pharmacological stress CMR test
Description: A bicycle ergometry combined with pharmacoligical stress test is performed. High sensitive Troponin is taken before and after the stress test.
Study: NCT05714020

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Real rTMS
Description: Repetitive transcranial magnetic stimulation (rTMS) is applied to the primary motor cortex. The protocol consists of 15 minutes of 10Hz stimulation, 10 seconds on, 20 seconds off, at 90% RMT, for a total of 3000 pulses.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: A sham coil is also used to mimic the clicking sound of the transcranial magnetic coil and skin stimulation.
Study: NCT04863235

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Eight week behavioural change program aimed to increase physical activity plus information on general health topics among individuals with prediabetes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Eight week behavioural change program plus a self-compassion intervention aimed to increase physical activity among individuals with prediabetes.
Study: NCT04308304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1942
Description: MK-1942 1 mg, 5 mg, and/or 10 mg capsules taken twice daily (BID) by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil 5 mg and/or 10 mg tablets taken once daily (QD) by mouth.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: Donepezil 5 mg and/or 10 mg tablets taken once daily (QD) by mouth.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule matched to MK-1942 taken BID by mouth.
Study: NCT04674202

Intervention type: OTHER
Intervention: Phone interview
Description: The participant will have 2 phone interview in which they will be asked about their knowledge of direct oral anticoagulants.

Intervention type: OTHER
Intervention: Phone interview
Description: The participant will have 2 phone interview in which they will be asked about their knowledge of direct oral anticoagulants.
Study: NCT05767125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APRV
Description: Patients with moderate-to-severe ARDS were supported with APRV.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LTV
Description: Patients with moderate-to-severe ARDS were supported with LTV.
Study: NCT05180617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music therapy participants will interact both musically and verbally with the therapist and will be given a range of both electronic and acoustic instruments to choose from. Music therapy sessions will be based upon music improvisation, and as such participants are not required to have any previous instrument or other music experience and be invited to improvise freely using the instruments. The music therapist will accompany participants in the improvisation. This provides participants with an opportunity to connect with emotions and feelings connected to hidden psychic material. Following improvisations, the therapist and client will identify these moments of interest which can be further explored either verbally or through further improvisation. The music created within sessions will be recorded and participants can take a copy of the recordings home and it will be used in the therapeutic monitoring and analysis of sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music therapy participants will interact both musically and verbally with the therapist and will be given a range of both electronic and acoustic instruments to choose from. Music therapy sessions will be based upon music improvisation, and as such participants are not required to have any previous instrument or other music experience and be invited to improvise freely using the instruments. The music therapist will accompany participants in the improvisation. This provides participants with an opportunity to connect with emotions and feelings connected to hidden psychic material. Following improvisations, the therapist and client will identify these moments of interest which can be further explored either verbally or through further improvisation. The music created within sessions will be recorded and participants can take a copy of the recordings home and it will be used in the therapeutic monitoring and analysis of sessions.
Study: NCT04841135

Intervention type: OTHER
Group type: OTHER
Intervention: Multiomics quantification
Description: One time blood, stool and urine samples will be taken.

Intervention type: OTHER
Group type: OTHER
Intervention: Multiomics quantification
Description: One time blood, stool and urine samples will be taken.

Intervention type: OTHER
Group type: OTHER
Intervention: Multiomics quantification
Description: One time blood, stool and urine samples will be taken.

Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnography
Description: Facultative polysomnography

Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnography
Description: Facultative polysomnography
Study: NCT04368806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JointStem
Description: Autologous Adipose tissue derived Mesenchymal Stem Cells (AdMSC)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Normal Saline with autologous Serum
Study: NCT06403137

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance exercise
Description: 4 single-leg exercise sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: 4 single-leg exercise sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: 4 single-leg exercise sessions

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standardized diet
Description: Fully standardized provided energy-balanced diet providing recommended daily allowance for protein.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized diet
Description: Fully standardized provided energy-balanced diet providing recommended daily allowance for protein.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized diet
Description: Fully standardized provided energy-balanced diet providing recommended daily allowance for protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant protein supplement
Description: Dissolved in water with breakfast and prior to sleep.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin supplement
Description: Dissolved in water with breakfast and prior to sleep.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk protein supplement
Description: Dissolved in water with breakfast and prior to sleep.